Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 × PD-L1 Antibody-Drug Conjugate.
Chenggang Li, Jun Yao, Junjie Yang...
https://pubmed.ncbi.nlm.nih.gov/40499141/Actively Recruiting
Led by DualityBio Inc. · Updated on 2026-06-05
360
Participants Needed
36
Research Sites
N/A
Total Duration
Researchers are conducting a Phase 12a clinical trial to evaluate DB-1419, a drug given by intravenous injection, for people with advanced or metastatic solid tumors that have relapsed, progressed, or have no standard treatment options. This open-label, multicenter study aims to assess the safety, tolerability, how the drug is processed in the body, and early signs of antitumor activity in participants. The trial is sponsored by DualityBio Inc. and includes adults aged 18 and older with measurable tumors or bone-only disease in some cases. Participants receive DB-1419 at various dose levels ranging from Dose Level 1 up to Dose Level 9. The study is non-randomized and includes dose escalation and dose expansion phases to determine the maximum tolerated dose and recommended dose for further study. The drug is administered by vein injection, and dosing cycles last either 14 or 21 days, with up to 8 cycles monitored for pharmacokinetics and immune response markers. During the study, participants undergo tumor assessments using RECIST v1.1 criteria to measure response, as well as monitoring for adverse events and serious adverse events for up to 90 days after the last dose or before new cancer treatment begins. Additional tests include cardiac function evaluation, blood tests for drug levels and antibodies, and physical exams. The study tracks progression-free survival, overall survival, and other safety and efficacy outcomes for approximately 12 months. Participants must provide consent and comply with study procedures throughout this period.
CONDITIONS
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
M
Milly Zang
C
Cathy Li
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
DualityBio Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | DB-1419 (Investigation) | Standard Chemotherapy |
|---|---|---|
| What is this treatment? | DB-1419 is an investigational antibody-drug conjugate targeting B7-H3 and PD-L1, given as an intravenous infusion in dose escalation and expansion cohorts. | Standard current-care regimens include cytotoxic chemotherapy options that may vary based on tumor type, prior treatments, and patient health, supported by clinical guidelines. |
| Role in the study | Participants receive DB-1419 across escalating dose cohorts to evaluate safety, tolerability, and preliminary anti-tumor activity. | Patients outside the study would normally receive guideline-recommended cytotoxic chemotherapy for advanced/metastatic solid tumors with prior therapy failure. |
| Primary use or purpose | Used in a first-in-human trial for dose escalation, expansion, and evaluation of responses in advanced/metastatic solid tumors. | Chemotherapy is used as a disease-modifying treatment aiming to reduce tumor burden or control progression after prior therapy failure. |
| How is it given? | DB-1419 is administered by intravenous injection across multiple dose levels, typically in 21- or 14-day cycles. | Chemotherapy regimens are mostly given intravenously or orally depending on tumor histology and patient factors; cycle lengths and drugs vary according to guidelines. |
| Evidence status and maturity | Human efficacy and safety data are not yet established; preclinical studies show anti-tumor activity for DB-1419. | Efficacy, safety, and outcome data for standard chemotherapy regimens are established in large published studies and reflected in guidelines. |
| Important limitations | Potential safety, tolerability, and efficacy are not yet established in humans; only preclinical evidence exists. | Chemotherapy may have limited effectiveness and considerable side effects in relapsed/refractory advanced solid tumors; response rates often decline with prior treatment. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 12 months or until disease progression, withdrawal, or starting new anticancer treatment
Participants receive the study drug DB-1419 by intravenous injection at assigned dose levels to assess safety, tolerability, and preliminary antitumor activity.
Repeated visits for drug administration and assessments over up to 8 cycles (each cycle 14 or 21 days)
Duration - Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first
Participants are monitored for adverse events and survival outcomes after completing treatment.
Approximately 1 to 2 visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
17
Have more questions? Get in touch with our team for quick support
Chenggang Li, Jun Yao, Junjie Yang...
https://pubmed.ncbi.nlm.nih.gov/40499141/DualityBio Inc.
Lead Sponsor